Bronchoscopic Tumour Ablation for Immune Priming to Enhance Neoadjuvant Chemotherapy and Immunotherapy in Resectable Non-Small Cell Lung Cancer (IMPRINT Study): A Single-Arm Open Label Feasibility Study (ANZCTR) - Oct 2, 2026 - P=N/A | N=29 | Not yet recruiting | Sponsor: Royal Melbourne Hospital
New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor
|